Insights

Top brokers just upgraded the ResMed (ASX:RMD) share price and this other ASX stock

Leading brokers just upgraded two ASX stocks to their buy list even as we enter what could be the most trying week since COVID‐19.
The post Top brokers just upgraded the ResMed (ASX:RMD) share price and this other ASX stock appeared first on Motley Fool Australia. –

ASX broker upgrade

Leading brokers just upgraded two ASX stocks to their buy list even as we enter what could be the most trying week since COVID‐19.

The US presidential election and the shutdown of major economies due to the resurgence of COVID cases are adding to the jitters.

The S&P/ASX 200 Index (Index:^AXJO) is holding up reasonably well today considering, although that could quickly change.

ResMed share price reawakens

But this wasn’t enough to keep brokers from upgrading the Resmed CDI (ASX: RMD) share price. Credit Suisse upgraded the stock to “outperform” from “neutral” following the latest quarterly results from the sleep treatment device maker.

“We believe RMD is uniquely placed to benefit from a behavioural shift to home healthcare post COVID due to its increased investment in its out‐of‐hospital platforms over the past ~5 years,” said the broker.

“On an underlying basis, we estimate CPAP device sales declined 2% in 1Q21 (vs CSe  ‐10%), indicating a strong recovery post lock‐downs.”

Even if the UK and parts of Europe goes back into a lockdown, management indicated sales of its CPAP devices should continue to improve.

Credit Suisse’s 12-month price target on ResMed is $31 a share.

RMD results ahead of consensus

Another broker that upgraded the ResMed share price is UBS, which lifted its rating on the stock to “buy” from “neutral”.

“RMD 1Q21 result was well ahead of our (and consensus) forecasts, with group revenue +6% ahead of UBSe (equating to ~US$45mn),” said UBS.

“Pleasingly, sleep-related sales (flow gens and masks) recovered faster than anticipated.”

UBS’s 12-month price target on RMD’s US-listed stock is US$210 a share.

Broker upgrade could rev SGF share price

Meanwhile, the SG Fleet Group Ltd (ASX: SGF) share price also found favour with Morgan Stanley.

The broker upgraded its recommendation on the novated leasing and fleet management group to “overweight” from “equal-weight”. It believes management’s 1HFY21 guidance is too conservative.

“A$22-24m NPAT guidance implies earnings are almost back to pre-Covid-19 levels and does not include drivers outside of SGF’s control, particularly as Victoria comes out of lockdown,” said the broker.

“SGF has described Victorian novated exposure as ‘significant’ so easing of restrictions likely a tailwind.”

The positive updates from Eagers Automotive Ltd (ASX: APE), Bapcor Ltd (ASX: BAP) and McMillan Shakespeare Limited (ASX: MMS) also indicate that the auto industry has turned a corner.

Morgan Stanley’s 12-month price target on the SG Fleet share price is $2.30 a share.

These Dividend Stocks Could Be Your Next Cash Kings (FREE REPORT)

Motley Fool Australia’s Dividend experts recently released a brand-new FREE report revealing 3 dividend stocks with JUICY franked dividends that could keep paying you meaty dividends for years to come.

Our team of investors think these 3 dividend stocks should be a ‘must consider’ for any savvy dividend investor. But more importantly, could potentially make Australian investors a heap of passive income.

Don’t miss out! Simply click the link below to grab your free copy and discover these 3 high conviction stocks now.

Click Here For Your Free Stock Report

Returns As of 6th October 2020

More reading

Motley Fool contributor Brendon Lau has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Bapcor. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Top brokers just upgraded the ResMed (ASX:RMD) share price and this other ASX stock appeared first on Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!